Lung macrophages play a pivotal role in diseases like idiopathic pulmonary fibrosis. Two types of macrophages—the white blood cells that defend the body by killing microbes, removing dead cells and stimulating immune responses—are ...
Jul 3, 2025
0
97
A new drug for pulmonary fibrosis has reduced disease progression by more than 50% over a 52-week treatment in two clinical trials. Pulmonary fibrosis is a very serious disease, with a life prognosis of 3 to 5 years after ...
May 21, 2025
0
3
Researchers at Tulane University have identified a potential new way to treat idiopathic pulmonary fibrosis (IPF), a deadly and currently incurable lung disease that affects more than 3 million people worldwide.
Apr 22, 2025
0
2
A research team led by the Guangzhou Institutes of Biomedicine and Health of the Chinese Academy of Sciences has constructed a comprehensive spatiotemporal atlas of developing mouse lungs, revealing new molecular and cellular ...
Apr 7, 2025
0
0
Rutgers Health researchers have discovered that networks of misplaced immune cells drive an aggressive lung disease, potentially opening a path to new treatments for a condition that kills 80% of patients within a decade.
Mar 27, 2025
0
0
Researchers have found a potential new way to slow the progression of lung fibrosis and other fibrotic diseases by inhibiting the expression or function of Piezo2, a receptor that senses mechanical forces in tissues including ...
Mar 25, 2025
0
0
Roughly one in five (21 percent) of idiopathic pulmonary fibrosis (IPF) deaths might be related to occupational exposures, according to research published in the March 6 issue of the U.S. Centers for Disease Control and Prevention ...
Mar 10, 2025
0
0
An international team of researchers has, for the first time, created a detailed map of the location and identity of individual cells in the adult lung, both from healthy lungs and in lungs from people affected by chronic ...
Feb 19, 2025
0
4
Pulmonary fibrosis is a rare, chronic disease that causes scarring in the lungs, making breathing difficult for people who suffer with it. And, as University of South Florida pulmonologist Dr. Jose Herazo-Maya knows all too ...
Jan 23, 2025
0
1
Weill Cornell Medicine researchers have found that pharmacy benefit managers (PBMs)—organizations that negotiate access to medicines for most patients in the United States—steer patients to use their own pharmacies. However, ...
Jan 10, 2025
0
0
Idiopathic pulmonary fibrosis (IPF) (or cryptogenic fibrosing alveolitis (CFA) / or Idiopathic Fibrosing Interstitial Pneumonia) is a chronic, progressive form of lung disease characterized by fibrosis of the supporting framework (interstitium) of the lungs. By definition, the term is used only when the cause of the pulmonary fibrosis is unknown ("idiopathic").
Microscopically, lung tissue from patients shows a characteristic set of histologic/pathologic features known as usual interstitial pneumonia (UIP). UIP is therefore the pathologic counterpart of IPF.
This text uses material from Wikipedia licensed under CC BY-SA
